Table 4.

Four-year survival rates of patients with newly diagnosed myeloma based on initial treatment and myeloma risk classification

Risk group	IMiD/PI (n = 134)	PI/Alkylator (n = 152)	Doublet (n = 176)
Standard-risk myeloma (n = 352)a	84.7%	83.4%	87.6%
High-risk myeloma (n = 110)a	70.2%	73.0%	60.9%

IMiD/PI immunomodulatory drug–proteasome inhibitor containing triplet combination; PI/Alkylator proteasome inhibitor–alkylating agent containing triplet combination

^aAmong patients with high-risk myeloma (n = 110), 48 received IMiD/PI, 39 PI/Alkylator, and 23 doublet. Among patients with standard-risk myeloma (n = 369), 86 received IMiD/PI, 113 PI/Alkylator, and 153 doublet